Gemcitabine diphosphate (dFdCDP) inhibits ribonucleotide reductase, which catalyses formation of deoxynucleotide triphosphates required for DNA synthesis. When incorporated into DNA, ...

Gemcitabine is then phosphorylated into gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (DCK), and dFdCMP is subsequently phosphorylated to gemcitabine diphosphate (dFdCDP) and ...

Subsequently, dFdCMP is phosphorylated to gemcitabine diphosphate (dFdCDP) by CMPK1, and then dFdCDP is converted to gemcitabine triphosphate (dFdCTP; major active metabolite) by nucleotide kinases.

Background: Motesanib diphosphate is an oral investigational, highly selective inhibitor of VEGF, PDGF and Kit receptors. In advanced cancer, inhibition of EGFR and VEGFR, with or without chemotherapy ...

Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients. Skip to main content.

In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 ...

Gemcitabine chemotherapy is used for advanced cancers of the breast, lungs, ovaries, and pancreas. Learn about delivery, side effects, effectiveness, and more.

The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02).

Gemcitabine has been used since 1997 as a treatment for advanced unresectable pancreatic cancer, and it is a potent radiosensitizer. Dr. Loehrer and colleagues examined the role, among patients ...

Yes. The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to gemcitabine — the combination was planned based ...

PATIENTS AND METHODS: Patients with unresectable LMS of uterine (n = 29) or other (n = 5) primary sites who did not respond to zero to two prior chemotherapy regimens were enrolled onto a phase II ...

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to ...